Boston Therapeutics is a pharmaceutical company focused on developing and commercializing novel compounds based on complex carbohydrate chemistry. The company’s product pipeline is focused therapeutic molecules that address Type 2 diabetes. These products currently include PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation; and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. For more information, visit the company’s website at www.bostonti.com.